BRIDGEWATER, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (OTCBB: NVDL) (the “Company”), a specialty pharmaceutical company developing oral spray formulations for a broad range of prescription products, reported financial results for its second quarter and six months ended June 30, 2010. For the quarter and six months ended June 30, 2010, NovaDel reported a net loss of $1.1 million, or $0.01 per share, and $2.4 million, or $0.03 per share, respectively, compared to a net loss of $1.7 million, or $0.03 per share, and $3.8 million, or $0.06 per share, respectively, for the quarter and six months ended June 30, 2009. As of June 30, 2010, NovaDel’s cash and cash equivalents were $3.1 million.